Angela Alistar

3.9k total citations
48 papers, 630 citations indexed

About

Angela Alistar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Angela Alistar has authored 48 papers receiving a total of 630 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Angela Alistar's work include Cancer Immunotherapy and Biomarkers (12 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Cancer, Hypoxia, and Metabolism (9 papers). Angela Alistar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Cancer, Hypoxia, and Metabolism (9 papers). Angela Alistar collaborates with scholars based in United States, New Zealand and United Kingdom. Angela Alistar's co-authors include Timothy S. Pardee, Eric Van Cutsem, Marc Buyse, Michael A. Black, Lance D. Miller, Philip A. Philip, Andrew Ferretti, Shrikanta Chattopadhyay, Yifan Wang and Sarah A. Bertino and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Angela Alistar

45 papers receiving 617 citations

Peers

Angela Alistar
Jinli Wei China
Birte Möhlendick Germany
Iris Mimpen United States
Fubiao Kang China
Abdul Rouf Banday United States
Grace Tin‐Yun Chung Hong Kong
Chunxiao Liu China
Sonia Cellot Canada
Mona S. Abdellateif Egypt
Yasunori Nakagawa Japan
Jinli Wei China
Angela Alistar
Citations per year, relative to Angela Alistar Angela Alistar (= 1×) peers Jinli Wei

Countries citing papers authored by Angela Alistar

Since Specialization
Citations

This map shows the geographic impact of Angela Alistar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Alistar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Alistar more than expected).

Fields of papers citing papers by Angela Alistar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Alistar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Alistar. The network helps show where Angela Alistar may publish in the future.

Co-authorship network of co-authors of Angela Alistar

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Alistar. A scholar is included among the top collaborators of Angela Alistar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Alistar. Angela Alistar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chung, Vincent, Angela Alistar, Carlos Becerra, et al.. (2025). Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. The Oncologist. 30(1). 4 indexed citations
2.
Tolcher, Anthony W., Drew Rasco, Melissa L. Johnson, et al.. (2024). Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2521–2521. 2 indexed citations
3.
Sahai, Vaibhav, Kent A. Griffith, David B. Zhen, et al.. (2024). Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).. Journal of Clinical Oncology. 42(16_suppl). 4116–4116. 2 indexed citations
4.
Xie, Hao, Anthony B. El-Khoueiry, Angela Alistar, et al.. (2024). A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).. Journal of Clinical Oncology. 42(16_suppl). 3078–3078. 2 indexed citations
5.
Waltzman, Roger J., Diana L. Hanna, Angela Alistar, et al.. (2024). Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2583–2583. 3 indexed citations
6.
Moser, Justin C., Angela Alistar, Ezra E.W. Cohen, et al.. (2023). 618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors. SHILAP Revista de lepidopterología. A704–A704. 4 indexed citations
7.
8.
9.
Ferretti, Andrew, Tomasz Kula, Yifan Wang, et al.. (2020). Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity. 53(5). 1095–1107.e3. 182 indexed citations
10.
Chung, Vincent, Angela Alistar, Ben George, et al.. (2020). SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma. Annals of Oncology. 31. S218–S218. 6 indexed citations
11.
12.
Page, B.R., Edina C. Wang, E. McTyre, et al.. (2017). Gamma Knife radiosurgery for brain metastases from gastrointestinal primary. Journal of Medical Imaging and Radiation Oncology. 61(4). 522–527. 6 indexed citations
13.
Alistar, Angela, et al.. (2017). Anti-mitochondrial therapy in bile duct cancer.. Journal of Clinical Oncology. 35(15_suppl). e15661–e15661. 1 indexed citations
14.
Miller, Lance D., Michael A. Black, Cristin G. Print, et al.. (2016). Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunology Research. 4(7). 600–610. 76 indexed citations
15.
Lycan, Thomas, Timothy S. Pardee, W. Jeffrey Petty, et al.. (2016). A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS ONE. 11(10). e0164244–e0164244. 49 indexed citations
16.
Alistar, Angela, et al.. (2016). CPI-613 enhances FOLFIRINOX response rate in stage IV pancreatic cancer. Annals of Oncology. 27. vi228–vi228. 7 indexed citations
17.
Sanoff, Hanna K., Richard D. Kim, Anastasia Ivanova, et al.. (2015). Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Investigational New Drugs. 33(2). 505–509. 14 indexed citations
18.
Alistar, Angela, Jeff W. Chou, Srikanth Nagalla, et al.. (2014). Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Medicine. 6(10). 80–80. 42 indexed citations
19.
Alistar, Angela, Max W. Sung, Michelle Kim, & Randall F. Holcombe. (2012). Clinical Pathways for Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Cancer. 43(4). 532–540. 6 indexed citations
20.
Alistar, Angela, et al.. (2009). A study on the prevalence of skeletal osteosarcoma in dogs and cats.. Lucrari Stiintifice - Universitatea de Stiinte Agricole a Banatului Timisoara, Medicina Veterinara. 42(2). 102–106. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jinli Wei Breakdown of academic impact, for papers by Birte Möhlendick Breakdown of academic impact, for papers by Iris Mimpen Breakdown of academic impact, for papers by Fubiao Kang Breakdown of academic impact, for papers by Abdul Rouf Banday Breakdown of academic impact, for papers by Grace Tin‐Yun Chung Breakdown of academic impact, for papers by Chunxiao Liu Breakdown of academic impact, for papers by Sonia Cellot Breakdown of academic impact, for papers by Mona S. Abdellateif Breakdown of academic impact, for papers by Yasunori Nakagawa
Rankless by CCL
2026